Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
Steven Lim, Chee Peng Hor, Kim Heng Tay, et al.
JAMA Internal Medicine (2022) Vol. 182, Iss. 4, pp. 426-426
Open Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

Ivermectin for preventing and treating COVID-19
Maria Popp, Stefanie Reis, Selina Schießer, et al.
Cochrane library (2022) Vol. 2024, Iss. 3
Open Access | Times Cited: 154
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 120
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19
Susanna Naggie, David R. Boulware, Christopher J. Lindsell, et al.
JAMA (2022) Vol. 328, Iss. 16, pp. 1595-1595
Open Access | Times Cited: 76
Epigallocatechin gallate as a nutraceutical to potentially target the metabolic syndrome: novel insights into therapeutic effects beyond its antioxidant and anti-inflammatory properties
Yonela Ntamo, Babalwa Jack, Khanyisani Ziqubu, et al.
Critical Reviews in Food Science and Nutrition (2022) Vol. 64, Iss. 1, pp. 87-109
Closed Access | Times Cited: 35
Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype
Milena Soriano Marcolino, Karina Cardoso Meira, Nathália Sernizon Guimarães, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 30
Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19)
Hongyan Li, Menghan Gao, Hailong You, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e148-e154
Open Access | Times Cited: 27
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities
Rahul Kumar, Öznur Aktay-Cetin, Vaughn D. Craddock, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 1, pp. e1011063-e1011063
Open Access | Times Cited: 15
A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?
Mohsen Nabi‐Afjadi, Fatemeh Mohebi, Hamidreza Zalpoor, et al.
Inflammopharmacology (2023) Vol. 31, Iss. 1, pp. 21-35
Open Access | Times Cited: 14
Ivermectin for treatment of COVID-19: A systematic review and meta-analysis
Zhilong Song, Senyuan Shi, Yongli Zhang
Heliyon (2024) Vol. 10, Iss. 6, pp. e27647-e27647
Open Access | Times Cited: 4
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials
Nathália Mariana Santos Sansone, Matheus Negri Boschiero, Fernando Augusto Lima Marson
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2206-2206
Open Access | Times Cited: 4
Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients
Arman Shafiee, Mohammad Mobin Teymouri Athar, Omid Kohandel Gargari, et al.
Virology Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 21
Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment
Dora Buonfrate, Paola Rodari, Beatrice Barda, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 14, pp. 1617-1628
Open Access | Times Cited: 19
Unravelling the Complex Interplay of Age, Comorbidities, and Multimorbidities in COVID-19 Disease Progression: Clinical Implications and Future Perspectives
Maria Shoukat, Haseeb Khan, Wajid Munir, et al.
Heliyon (2024) Vol. 10, Iss. 15, pp. e35570-e35570
Open Access | Times Cited: 3
Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder
Tushar Saha, Shubhra Sinha, Rhodri Harfoot, et al.
Pharmaceutics (2022) Vol. 14, Iss. 7, pp. 1432-1432
Open Access | Times Cited: 15
Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations
Kunlakanya Jitobaom, Chompunuch Boonarkart, Suwimon Manopwisedjaroen, et al.
BMC Pharmacology and Toxicology (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Care for adults with COVID ‐19: living guidelines from the National COVID ‐19 Clinical Evidence Taskforce
Heath White, Steve McDonald, Bridget E. Barber, et al.
The Medical Journal of Australia (2022) Vol. 217, Iss. 7, pp. 368-378
Open Access | Times Cited: 14
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic
Edi Dharmana, Juliane Brun, Michelle L. Hill, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 354-354
Open Access | Times Cited: 8
Knowledge, attitude and prevalence of ivermectin use as coronavirus disease treatment: A cross-sectional study among a Malaysian population
Tar’ali Filza Nur Athirah, Abdul Jalil Aina Amanina, Nor Afendi Nor Safwan Hadi
Malaysian Family Physician (2024) Vol. 19, pp. 2-2
Open Access | Times Cited: 2
Clinical update on COVID-19 for the emergency and critical care clinician: Medical management
Brit Long, Summer Chavez, Brandon M Carius, et al.
The American Journal of Emergency Medicine (2022) Vol. 56, pp. 158-170
Open Access | Times Cited: 13
Autophagy Modulators in Coronavirus Diseases: A Double Strike in Viral Burden and Inflammation
Rafael Cardoso Maciel Costa Silva, Jhones Sousa Ribeiro, Gustavo Peixoto Duarte da Silva, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 13
Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection
Alexander J. McAuley, Petrus Jansen van Vuren, Muzaffar-Ur-Rehman Mohammed, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2417-2417
Open Access | Times Cited: 13
Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages
Xin Wang, Han Wang, Guosheng Yin, et al.
Heliyon (2023) Vol. 9, Iss. 3, pp. e14059-e14059
Open Access | Times Cited: 7
Natural products as a source of Coronavirus entry inhibitors
Dávid Szabó, Andrew Crowe, Cyril Mamotte, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 2
Is Ivermectin Effective in Treating COVID-19?
Shuangshuang Yang, Shan Shen, Ning Hou
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top